Acadia Pharmaceuticals (ACAD) Interest Expenses (2018 - 2020)

Acadia Pharmaceuticals' Interest Expenses history runs 16 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 90.75% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 90.75% YoY), while the FY2025 annual figure was $79.3 million, up 275.21% from the prior year.
• Interest Expenses for Q1 2026 stood at $5.9 million, up from $3.2 million in the prior quarter.
• The five-year high for Interest Expenses was $71.4 million in Q1 2023, with the low at $2.4 million in Q4 2022.
• The 5-year median for Interest Expenses is $9.9 million (2024), against an average of $21.7 million.
• The sharpest annual moves came in 2023 and 2026: Interest Expenses jumped 689.51% in 2023, then plunged 90.75% in 2026.
• Acadia Pharmaceuticals' Interest Expenses stood at $2.4 million in 2022, then advanced by 1.4% to $2.4 million in 2023, then gained by 7.52% to $2.6 million in 2024, then increased by 24.05% to $3.2 million in 2025, then surged by 85.22% to $5.9 million in 2026.
• Business Quant data shows ACAD's Interest Expenses at $5.9 million in Q1 2026, $3.2 million in Q4 2025, and $11.4 million in Q3 2025.